用于检测卵巢癌的基于蛋白质的特征标志物的开发与验证
Development and validation of a protein-based signature for the detection of ovarian cancer.
作者信息
Kim Kyongjin, Visintin Irene, Alvero Ayesha B, Mor Gil
机构信息
Department of Obstetrics, Gynecology and Reproductive Sciences, Reproductive Immunology Unit, Yale University School of Medicine, 333 Cedar Street FMB 301, New Haven, CT 06520, USA.
出版信息
Clin Lab Med. 2009 Mar;29(1):47-55. doi: 10.1016/j.cll.2009.02.001.
To overcome the significant mortality associated with ovarian cancer, a highly sensitive and specific screening test is urgently needed. CA-125 testing is used to monitor response to chemotherapy, detect recurrence, and detect late stage ovarian cancer. However, CA-125 testing, alone or in combination with ultrasonography, has not been adequate for early detection of ovarian cancer. This article discusses the authors' recent report of a novel multiplex assay that uses a panel of six serum biomarkers: leptin, prolactin, osteopontin, insulin-like growth factor II (IGF-II), macrophage inhibitory factor (MIF), and CA-125. The combination of these six proteins yielded 95.3% sensitivity and 99.4% specificity. The application of this test in the clinical context and the most appropriate population, which could benefit from the test, are discussed.
为了克服与卵巢癌相关的高死亡率，迫切需要一种高度敏感和特异的筛查测试。CA-125检测用于监测化疗反应、检测复发以及检测晚期卵巢癌。然而，单独的CA-125检测或与超声检查联合使用，对于卵巢癌的早期检测都还不够充分。本文讨论了作者最近关于一种新型多重检测法的报告，该方法使用一组六种血清生物标志物：瘦素、催乳素、骨桥蛋白、胰岛素样生长因子II（IGF-II）、巨噬细胞抑制因子（MIF）和CA-125。这六种蛋白质的组合产生了95.3%的灵敏度和99.4%的特异性。本文还讨论了该测试在临床环境中的应用以及可能从该测试中受益的最合适人群。
Zotero 插件